REGENERATIVE MEDICINE ORGANIZATION CONFERENCE SPEAKER AND TOPIC SCHEDULE ANNOUNCED

Las Vegas, Nevada – January 29 – The Regenerative Medicine Organization (RMO) today announced its line of topics and world-class speakers for its 4th annual conference on new and emerging treatments to heal damaged organs and tissues.

The Regenerative Medicine Conference, focusing on “The Convergence of Science, Business, Medicine and Politics,” is open to the public, will be held at the Mirage Hotel in Las Vegas February 26th through February 28th 2007.

Regenerative Medicine comprises treatments designed to regenerate damaged tissues or organs by using the latest advances in science and medicine to help the body heal itself. Many fields in medicine and biology contribute to this emerging approach involving tissue engineering, cell biology, genetics, and pharmacology. The cost efficiencies inherent in cutting edge bio- and medical-technologies of regenerative medicine will significantly lower the cost of healthcare, much of which is derived from cardiovascular disease and aging, the areas on which regenerative medicine focuses.

The following is the Regenerative Medicine Conference Schedule and Speaker schedule:

February 26: The Science of Regenerative Medicine

“Therapeutic Angiogenesis in Cardiac Disease"
Lynne Wagoner, MD, FACC, Director of the Section of Heart Failure and Cardiac Transplantation at the University of Cincinnati Medical Center as well as Cardiac Services. Principal Investigator in twelve ongoing funded studies in heart failure. Awarded the “Individual National Research Service Award” from the National Institute of Health.

“Regenerative Therapy in Degenerative Disc Disease: Does Ischemia Play a Role?”
Vert Mooney, MD, Emeritus Professor of Orthopedic Surgery at the University of California, San Diego School of Medicine. Director of the US Spine & Sports Foundation.

“Tissue Engineering of Bone To Explore Metastasis“
Michael Rosenblatt, MD, Professor of Physiology and Medicine and Dean at Tufts University School of Medicine. Former Professor of Medicine at Harvard Medical School and Vice President Merck & Co. where he assisted in the development of Fosamax for the treatment of osteoporosis.

“Geriatric Medicine-A Social, Political & Clinical Perspective”
Steven Phillips, MD, Director at Geriatric Care of Nevada, Chairman-Elect for the American Geriatrics Society.

"Regenerative Medicine-What Does it Mean?”
Thomas J. Stegmann, MD,FETCS, Co-founder and Co-President of CardioVascular BioTherapeutics, Inc. For the past 13 years, he has been working in the area of neo-angiogenesis and human growth factors. Author of the book, “New Vessels for the Heart.” Former Director of the Department of Thoracic and Cardiovascular Surgery at the Fulda Medical Center in Germany.

“Non-Angiogenic Activities of FGF-1"
Kenneth Thomas, PhD, Vice President of Research & Development of CardioVascular BioTherapeutics, Inc, formerly with Merck in the development of proteins for 20 years.

"Bone Morphogenic Proteins Use in Bone Fracture Healing and Spinal Fusion"
Vance Gardner, MD, Executive Director of the Orthopedic Education and Research Institute of Southern California, a board-certified orthopedic surgeon.

“Regenerative Medicine and Stroke”
Scott Selco, MD, PhD, Medical Director of Stroke Care, The Nevada Neurosciences Institute.

February 27: The Operational Side of Regenerative Medicine

“Patient Selection Process for Clinical Trials”
Ginger Conway, MSN, RN, CNP Field Service Assistant Professor Division of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati Medical Center.

“The Growing Cost of Heart Disease”
Joseph A. Kaufman, MD, Chief Medical Officer and Vice President of Medical Affairs for Sierra Health Services, a managed care company selected as a "Forbes Platinum 400.”

“Diagnostic Imaging to Identify Ischemia”
F. David Rollo, MD, PhD, FACC, FACNP, President of CellPoint Corporation, formerly Chief Medical Officer with Philips Medical Systems. MS in Radiological Physics from University of Miami, a Ph.D. in Physics from Johns Hopkins and an M.D. from Upstate Medical Center in Syracuse.

“Preliminary Economic Case of FGF-1”
David Balekdjian, Partner of The Bruckner Group, a strategy consulting company for the Pharmaceutical industry, co-author of “Drugmakers: A Dose of Reality” which describes how high drug prices pose a revenue risk for pharma and biotech companies.

“Intellectual Property in Biotechnology: Protecting Your Investment”
Thomas Ichim, Chief of Scientific Development for Medistem Laboratories, Inc. and Program Director for the global clinical research organization BioRASI.

“New Therapies for Hepatitis C”
Michael Russo, President of The Bruckner Group which provides strategic research for the Pharmaceutical industry. Founder of the first annual Hepatitis C Leadership Summit in 2005 to elevate the response to the growing Hepatitis C epidemic.

“How Financial Analysts Look at Biotech Companies”
Steven Zimmer, Financial analyst with Objective Capital. Masters in Molecular Biology with more than 25 years experience in corporate finance biotech and pharma.

“Structural Genomics and a New Paradigm for Chemical Drug Discovery"
Sung Hou Kim PhD, Chairman and Co-Founder of Plexxikon. Professor of the Department of Chemistry at the University of California, Berkeley, and head of the Berkeley Structural Genomics Center, Lawrence Berkeley National Laboratory. Received PhD from the University of Pittsburgh. Dr. Kim was a Fulbright Fellow and a Guggenheim Fellow.

February 28: The Molecular Basis of Regenerative Medicine

“Pegylated Proteins: Making Biologic Drugs That Stay in the Body”
Myung Park, PhD, Chief Executive Officer and President of BiopolyMed, Inc., a biotech company that develops drug delivery systems for protein/peptide drugs as well as small molecules. Received Ph.D. from Rutgers University on protein chemistry, formerly a group leader at Enzon where she conducted pegylation of numerous proteins and enzymes and was awarded the “Outstanding Scientist” award.

“Spinal Diseases and Regenerative Medicine“
Vance Gardner, MD, Executive Director of the Orthopedic Education and Research Institute of Southern California, a board-certified orthopedic surgeon who serves as an invited reviewer of the journal Spine.

“The Latest in Molecular Architecture: Designing New Drugs”
Michael Blaber, PhD, Associate Professor of the Department of Biomedical Sciences in the College of Medicine at Florida State University. Worked 5 years at Genentech, Inc. as a Research Assistant in the Protein Chemistry group. Studied structure/function relationships of murine glandular kallikreins in the laboratory of Dr. Ralph Bradshaw at the Department of Biological Sciences in the College of Medicine at UC Irvine where he earned his Ph.D. Postdoctoral work on structure of T4 lysozyme mutants.

“Proteomics and Disease: Reality and Myth”
Ralph Bradshaw, PhD, Professor and former Chairman of the Department of Physiology and Biophysics at the University of California, Irvine. Dr. Bradshaw is recognized as one of the world's foremost experts on protein biochemistry. His most noted work has been with nerve growth factor and fibroblast growth factor. Dr. Bradshaw is the founding father of the Protein Society and is on the editorial boards of over 15 journals in the fields of biochemistry, molecular biology, and cell biology.

“Phage Therapy: an Answer to Multiple Resistant Bacteria?”
Jack Jacobs, PhD, Chief Operating Officer of Phage Biotechnology Corporation, formerly Director of Basic Research at the Hitachi Chemical Research Center in Irvine, California and an adjunct Professor of Biological Chemistry at University of California-Irvine’s College of Medicine. Prior to that he was the head of the Department for Biological Chemistry at Merck Sharp & Dohm Research laboratories.


The 2007 Regenerative Medicine Organization 4th Annual Conference is sponsored by CardioVascular BioTherapeutics, Inc. and Phage Biotechnology Corporation. The community partners are The Nevada Development Authority and The Las Vegas Chapter of the American Heart Association.

About the Regenerative Medicine Organization

The Regenerative Medicine Organization is a non-profit, educational organization incorporated in the State of Nevada with the purpose of increasing awareness of regenerative medicine and to advance this understanding in the medical, scientific and public communities. It is a clearing house of information on regenerative medicine and treatments, which are discussed at a range of forums and conferences that bring together scientists, researchers and the medical community. Regenerative medicine is the future of health care.

Contacts:

Conference Attendance

John Laub
Executive Director
The Regenerative Medicine Organization
(702) 839-7222
www.regenmd.org

Media

Steve Stern
Stern And Company
(702) 734-3388
steve@sdsternpr.com